<--- Back to Details
First PageDocument Content
Pharmacology / Science / Design of experiments / Medical statistics / Food and Drug Administration / Cetuximab / Trastuzumab / Clinical trial / Good Clinical Practice / Clinical research / Pharmaceutical industry / Research
Date: 2012-06-22 04:07:03
Pharmacology
Science
Design of experiments
Medical statistics
Food and Drug Administration
Cetuximab
Trastuzumab
Clinical trial
Good Clinical Practice
Clinical research
Pharmaceutical industry
Research

Microsoft PowerPoint - h-4- .Article review and recent example.ppt

Add to Reading List

Source URL: www.ich.org

Download Document from Source Website

File Size: 354,60 KB

Share Document on Facebook

Similar Documents

Biology / Medicine / Biotechnology / Specialty drugs / Peptide hormones / Recombinant proteins / Eli Lilly and Company / Trastuzumab / Kiran Mazumdar-Shaw / Biosimilar / Biocon / Biopharmaceutical

Biocon Limited: Q1 FY17 Earnings Call Transcript July 22, 2016 Participants from Biocon’s Senior Management Team Kiran Mazumdar Shaw: Chairperson and Managing Director Arun Chandravarkar: CEO & Jt. Managing Director

DocID: 1qxjl - View Document

Biotechnology / Biology / Medicine / Recombinant proteins / Specialty drugs / Biosimilar / Drugs / Biopharmaceutical / Trastuzumab / Mylan / Pegfilgrastim / Filgrastim

Press Release Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20

DocID: 1q6vz - View Document

Patientinformation – tillæg til DBCG 2015-b,t og 2015-d,t (Trastuzumab) Antistofbehandling af brystkræft efter operation Denne information supplerer vores mundtlige information om den behandling, vi anbefaler dig. I

DocID: 1pKwx - View Document

Recombinant proteins / Peptide hormones / Generally Accepted Accounting Principles / Biotechnology / Eli Lilly and Company / Insulin analog / Biosimilar / Biocon / Trastuzumab / Pharmaceutical industry in India / Kiran Mazumdar-Shaw / Biopharmaceutical

FINAL Press Release Biocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore

DocID: 1pawe - View Document

Peptide hormones / Recombinant proteins / Specialty drugs / Biotechnology / Monoclonal antibodies / Trastuzumab / Biocon / Insulin glargine / Insulin / Biosimilar / Pharmaceutical industry in India / Biopharmaceutical

Investor Presentation June 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM

DocID: 1oSV0 - View Document